GV 1001 Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC)
NCT00509457
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
BIOLOGICAL:
GV 1001 Telomerase peptide
Sponsor
Oslo University Hospital
Collaborators
[object Object]
[object Object]